Publication:
Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients.

dc.contributor.authorEscalera, Carlos Rodríguez
dc.contributor.authorGuisado, Ángela María Zurita
dc.contributor.authorMateo, Francisco Javier
dc.contributor.authorBahamontes-Rosa, Noemí
dc.contributor.authorVillanueva, María Jesús García
dc.date.accessioned2023-05-03T13:35:19Z
dc.date.available2023-05-03T13:35:19Z
dc.date.issued2022-07-23
dc.description.abstractBelimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is not a review focusing on all real-life experience with belimumab to date that could help to describe how this drug behaves in the Spanish clinical setting. To describe the characteristics of SLE patients treated with belimumab added to standard of care in real-clinical setting in Spain. We conducted a comprehensive scoping review of real-world data (RWD) according to PRISMA Scoping Reviews Checklist and the framework proposed by Arksey and O'Malley. PubMed and EMBASE were searched without language restriction and hand searches of relevant articles were examined. We included data from 222 patients treated with belimumab for SLE included in 19 RWD studies conducted in Spain. The mean age was 40.9 years, 84.2% were female, and baseline scores SELENA-SLEDAI ranged between 5.9 and 12. Lupus nephritis basal prevalence was of 2.7%. The main reason for belimumab initiation was previous treatments lack of efficacy (69.7%) and the most common laboratory abnormalities were hypocomplementemia (40.9%), ANA + (34.2%), and anti-DNA (33.3%). The addition of belimumab to standard therapy was associated with a reduction of daily glucocorticoids intake in 1.4-11.1 mg at 6 months. Belimumab discontinuation was observed in 18.6% of patients. Our study helps to further explore the profile of SLE patients most likely to be treated with belimumab.
dc.identifier.doi10.1007/s10067-022-06287-9
dc.identifier.essn1434-9949
dc.identifier.pmcPMC9308486
dc.identifier.pmid35871173
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308486/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s10067-022-06287-9.pdf
dc.identifier.urihttp://hdl.handle.net/10668/20374
dc.issue.number11
dc.journal.titleClinical rheumatology
dc.journal.titleabbreviationClin Rheumatol
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.page.number3373-3382
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.pubmedtypeSystematic Review
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectB-cell-targeted therapy
dc.subjectBelimumab
dc.subjectReal-life experience
dc.subjectReal-world data
dc.subjectSteroid sparing
dc.subjectSystemic lupus erythematosus
dc.subject.meshAdult
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshBiological Products
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunosuppressive Agents
dc.subject.meshLupus Erythematosus, Systemic
dc.subject.meshMale
dc.subject.meshSpain
dc.subject.meshTreatment Outcome
dc.titleUse of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number41
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9308486.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format